Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 6-year-old girl diagnosed with monilethrix, experiencing hair fragility and loss after a fever, and showing improvement in hair density following treatment, despite persistent symptoms.

A new mutation, Glu402Lys, in hair keratin is linked to variable symptoms of monilethrix.

This study observed that minimal doses of the arotinoid RO 13-6298 successfully treated two cases of severe psoriasis and psoriatic arthritis unresponsive to traditional therapies, despite some side effects.

This study found that diphenylcyclopropenone (DPCP) was more effective and better tolerated than dinitrochlorobenzene (DNCB) in promoting hair regrowth in patients with alopecia areata.

In this case report, a novel missense mutation c.1360G>C (p.Ala454Pro) in the MBTPS2 gene was identified in a boy with typical IFAP syndrome and severe atopic features, although no phenotype/genotype correlation was established.

In these initial clinical studies, NAP monotherapy showed significant reductions in HBsAg levels among patients with chronic HBV, suggesting potential as part of future combination therapies.

This study found that the aromatic retinoic acid derivative Ro 10-9359 provided excellent results in 64% of severe psoriasis patients, especially in those with erythrodermic and pustular types, though relapses and side effects were noted.

This report suggests that tofacitinib may be beneficial for patients with nail disease unresponsive to other treatments.

This study reports that a pH-responsive nanosilver platform improved wound healing in mouse and rabbit models by targeting bacteria and supporting tissue repair more effectively than traditional silver nanoparticles.

In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.

This case report describes an 87-year-old woman diagnosed with type 3 autoimmune polyendocrine syndrome, highlighting the importance of recognizing and managing coexisting autoimmune conditions.

This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

In this study, a case of dissecting cellulitis of the scalp was reported in a man after starting dupilumab therapy, highlighting potential immune pathways involved and the importance of recognizing such paradoxical inflammatory reactions to prevent irreversible alopecia.

This review reports very low quality evidence for the effectiveness and safety of treatments in extensive resistant alopecia areata and emphasizes the need for high-quality randomized controlled trials.

This case study reported significant clinical improvement in a 26-year-old male with dissecting cellulitis of the scalp after treatment with upadacitinib, suggesting that JAK inhibitors may be a promising option for refractory cases, where standard treatments have limited success.

This review discusses existing forensic DNA phenotyping panels for biogeographical ancestry and externally visible characteristics and highlights major technical limitations, including terminology issues, genetic knowledge gaps, and technological debates; it reports no new results.

IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.

This case report details a 31-year-old woman with a subcutaneous nodule on her hand characterized by necrosis and lymphocytic infiltrate.

This review discusses the controversial non-inflammatory alopecia known as alopecia X, highlighting its unknown etiology and the variable effectiveness of various proposed treatments, but reports no new results.

This study reported the development of pH-responsive nanoparticles that effectively deliver vancomycin in a controlled manner, demonstrated enhanced antibacterial activity, and showed promise for clinical applications by targeting bacterial infection sites with programmable drug release.

In this case report, tofacitinib was associated with new hair growth on psoriasis lesions after three months of treatment.

In this study, researchers found that the JAK1/2 inhibitor ruxolitinib helped normalize tissue-specific autoimmunity in APECED patients by reducing inflammation and immune cell accumulation, but it was also linked to subclinical side effects like anemia and weight gain.

In this in vitro study, extracts from Tridax procumbens demonstrated potential antioxidant and anticancer activity against various human cancer cell lines, with notable efficacy in specific fractions.

This abstract describes a program with various presentations and events focused on Canadian excellence in rheumatology but reports no new research findings.

This study highlights that while advances in dermatology, such as biologics and JAK inhibitors, have improved treatments for conditions like atopic dermatitis and psoriasis, challenges remain, including issues with lasting efficacy and the need for more personalized therapies.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.